

20 February 2009

The Manager
Company Announcements Office
Australian Securities Exchange Limited
20 Bridge Street
Sydney NSW 2000



cyclomedica
molecularimaging
technegas

Cyclopharm Limited
ABN 74 116 931 250
Suite 630 Level 6
1 Queens Road
Melbourne Victoria 3004
Australia
T 61 3 9867 2811
F 61 3 9820 5957
www.cyclopharm.com

Profit upgrade

Cyclopharm Limited (ASX: CYC) expects a profit after tax for the full year ended 31 December 2008 of \$1.7 million. This result exceeds the guidance given in September 2008 by approximately 20%. This expectation is based upon internal management accounts and may be subject to change on completion and review of the Cyclopharm Group's final accounts.

This update is given to comply with the requirements of ASX Listing Rule 3.1 and ASX Guidance Note 8. Cyclopharm expects to release its full year results on 26 February 2009 and will provide a comprehensive overview of its full year performance on publication of those results.

Lodgement to sell Technegas in the United States

Cyclopharm lodged its application to sell Technegas in the United States (US) with the Food and Drug Administration (FDA) on 19 December 2008. Based on early dialogue with the FDA, we have decided to temporarily withdraw our application in order to adjust the content. We believe that the modifications will ultimately enable a more expeditious review.

While the decision to withdraw may have an impact on the timing of approval, we believe that our path forward is better defined for the feedback we have received. It is estimated that the FDA review period will take up to 12 months from the re-lodgement date.

We look forward to keeping our shareholders fully apprised as we work toward the goal of achieving approval to sell Technegas in the United States.

James McBrayer
Managing Director

Contact details:

Mr James McBrayer
Managing Director
Cyclopharm Limited
T: +61 2 9541 0411

Background

Cyclopharm Limited

Cyclopharm is a radiopharmaceutical company servicing the medical global medical community. The Company's mission is to enable nuclear medicine and other clinicians with the ability to improve patient care outcomes.

Cyclopharm achieves this objective through the provision of radiopharmaceutical products, Technegas (for lung imaging) and Molecular Imaging / PET radiopharmaceuticals (used in cancer, brain and cardiac imaging). Our customers are nuclear medicine departments located within hospitals and clinics.

Technegas

The Technegas technology is a structured ultra-fine dispersion of radioactive labeled carbon, produced by using dried Technetium-99m in a carbon crucible, micro furnaced for a few seconds at around 2,500°C. The resultant gaseous substance is inhaled by the patient (lung ventilation) via a breathing apparatus, which then allows multiple views and tomography imaging under a gamma or single photon emission computed tomography (SPECT) camera for the superior diagnosis of pulmonary emboli (blood clots in the lungs).

Positron Emission Tomography (PET)

PET radiopharmaceuticals target specific tissues / organs, concentrate there, and the attached radioisotope emits radiation, which is then detected by a PET or PET / CT gamma (collectively PET camera). These imaging modalities help physicians improve their ability to detect and determine the location, extent and stage of cancer, neurological disorders and cardiac disease. By improving diagnosis, PET scans aid physicians in selecting better courses of treatment, as well as assessing whether treatment is effective or should be changed.

Macquarie University Private Hospital and the Macquarie University School of Advanced Medicine

Macquarie University Private Hospital is an \$80 million joint venture development between Macquarie University and Dalcross Private Hospital. The development will establish a major medical precinct within the Macquarie University Research Park to complement the Allied Health teaching services offered by Macquarie University.

The Macquarie University Private Hospital will be a state of the art facility that will also deliver health education and research on site.